September 21, 2026 10:00 ET | Source: Smith & Nephew UK Ltd Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will highlight a suite of advanced solutions for shoulder repair and reconstruction at the International Congress for Shoulder and Elbow Surgery (ICSES) in Vancouver from September 22-25. Surgeons are invited to visit
September 18, 2026 16:32 ET | Source: Teva Pharmaceutical Industries Ltd PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from a discrete choice experiment highlighting preferred healthcare provider (HCP) treatment attributes when selecting a VMAT2 inhibitor for
September 18, 2026 16:31 ET | Source: Teva Pharmaceutical Industries Ltd PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new real-world data evaluating treatment continuity, healthcare resource utilization (HCRU) and clinical outcomes among adults with schizophrenia and bipolar I
September 18, 2026 16:30 ET | Source: Teva Pharmaceutical Industries Ltd PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of new olanzapine LAI (TEV-‘749) post hoc data from the pivotal SOLARIS Phase 3 trial as well as
September 17, 2026 01:33 ET | Source: Boehringer Ingelheim Ingelheim, Germany – Boehringer Ingelheim today announced the launch of PED Essentials, a comprehensive e-learning hub designed to help patient organizations generate high-quality patient experience data (PED), share these insights with healthcare stakeholders and analyze existing PED as an evidence base for advocacy. The learning hub comes at
September 16, 2026 08:03 ET | Source: Royal Philips September 16, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that two Philips-led public-private research collaborations have received ITEA Awards of Excellence 2026 for advancing AI-enabled innovation in healthcare. SYMPHONY received the ITEA Award of Excellence for “Exceptional Excellence” for
September 16, 2026 08:00 ET | Source: Teva Pharmaceutical Industries Ltd PARSIPPANY, N.J., and TEL AVIV, Israel, Sept. 16, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of LongActingImpact.com, a new educational website for healthcare providers (HCPs) with information to support informed treatment discussions
Strategic shareholders commit A$7.1 million at a premium to market, the Company’s fourth consecutive equity raise priced at a premium, alongside A$3.75 million of non-dilutive R&D Tax Incentive pre-financing September 16, 2026 00:33 ET | Source: Cambium Bio Limited SYDNEY, Sept. 16, 2026 (GLOBE NEWSWIRE) — Cambium Bio Limited (ASX: CMB) (“Cambium Bio” or the “Company”), a
September 15, 2026 05:00 ET | Source: Hummingbird Bioscience SINGAPORE, Sept. 15, 2026 (GLOBE NEWSWIRE) — Hummingbird Bioscience (“Hummingbird”), a biotherapeutics company discovering and developing transformative medicines for diseases with significant unmet need, today announced the appointment of Dr. James Garner as President. Dr. Garner will join Hummingbird Bioscience’s leadership team and work alongside Piers Ingram, PhD,
BEXLUTRY is the first radioligand equivalent for the treatment of GEP-NETs in adults and the first radioligand therapy from Curium™ approved by the FDA September 14, 2026 17:49 ET | Source: Curium BOSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) — Curium™ announced today that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA)
September 14, 2026 08:03 ET | Source: Teva Pharmaceutical Industries Ltd PARSIPPANY, N.J. and TEL AVIV, Israel, Sept. 14, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), a global biopharmaceutical company, today announced that its ordinary shares will begin trading today directly on the New York Stock Exchange (NYSE) completing the company’s planned
September 10, 2026 20:00 ET | Source: Avance Clinical TAIPEI, Taiwan, Sept. 10, 2026 (GLOBE NEWSWIRE) — Avance Clinical Taiwan has won the Australia-Taiwan Business Excellence Award at the 2026 Australia New Zealand Chamber of Commerce in Taiwan (ANZCham Taiwan) Business Awards, held at Shangri-La’s Far Eastern Plaza Hotel in Taipei. The award is one of only
September 10, 2026 08:00 ET | Source: Adagene Inc. Amended terms of agreement include a transition to an integrated asset and technology partnership. SAN DIEGO and SUZHOU, China, Sept. 10, 2026 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies today announced that Third
September 10, 2026 06:04 ET | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, Sept. 10, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it successfully priced its offering of approximately $4.9 billion (equivalent) of senior notes (the “Notes”). Teva expects to use the net proceeds from the offering,
Regulatory milestone strengthens Australia’s sovereign advanced therapeutics manufacturing capability September 10, 2026 01:08 ET | Source: VIRAL VECTOR MANUFACTURING FACILITY PTY. LTD. SYDNEY, Sept. 10, 2026 (GLOBE NEWSWIRE) — Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first viral vector Contract Development and Manufacturing Organisation (CDMO) advises that the Therapeutic Goods Administration (TGA) has granted the company
